[{"from": "human", "value": "Describe this molecule. [C][C][#C][C][=Branch1][C][=O][N][C][C][C@H1][Branch1][Ring2][C][Ring1][Branch1][N][C][=C][Branch1][#C][C][=C][Ring1][Branch1][C][=Branch1][C][=O][N][N][=C][Ring1][#Branch1][N][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][=C][Branch1][Branch2][C][=C][C][=C][Ring1][=Branch1][F][F]"}, {"from": "gpt", "value": "The molecule is an orally available irreversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) with potential antineoplastic activity. Upon administration, edralbrutinib covalently binds to and irreversibly inhibits BTK activity, thereby preventing the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This may inhibit the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes."}]